ArticleNeuro-oncology2015
Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation.
Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Plasma ECRG4 as a novel diagnostic marker for Alzheimer's disease associated with oligodendrocyte dysfunction.American journal of translational research · 2026Article
- Myc-associated zinc finger protein drives colorectal cancer metastasis through activating ubiquitin like with ring finger protein one.World journal of gastrointestinal oncology · 2025Article
- ECRG4 mediates host response to cutaneous infection by regulating neutrophil recruitment and adhesion receptor expression.PloS one · 2024Article
- Complex and pleiotropic signaling pathways regulated by the secreted protein augurin.Cell communication and signaling : CCS · 2023Review
- Article
- Is Autophagy Always a Barrier to Cisplatin Therapy?Biomolecules · 2022Review
- IL-4R alpha deficiency influences hippocampal-BDNF signaling pathway to impair reference memory.Scientific reports · 2020Article
- ECRG4 regulates neutrophil recruitment and CD44 expression during the inflammatory response to injury.Science advances · 2020Article
- Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma.Frontiers in pharmacology · 2020Review
- Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.Cellular and molecular life sciences : CMLS · 2019Article
- An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.Oncogene · 2019Article
- Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.Frontiers of medicine · 2019Review
- ECRG4: a new potential target in precision medicine.Frontiers of medicine · 2019Review
- Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis.Cancer gene therapy · 2018Article
- Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice.Schizophrenia bulletin · 2018Article
- Ecrg4 peptide is the ligand of multiple scavenger receptors.Scientific reports · 2018Article
- Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System.Frontiers in cellular neuroscience · 2018Review
- Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.International journal of molecular sciences · 2017Review
- A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer.Oncotarget · 2017Article
- Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report.Cellular oncology (Dordrecht, Netherlands) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundExtensive infiltration of brain tumors by microglia and macrophages is a hallmark of tumor progression, and yet the overall tumor microenvironment is characterized by an immunosuppressive phenotype. Here we identify esophageal cancer-related gene 4 (Ecrg4) as a novel thrombin-processed monocyte chemoattractant that recruits myeloid cells, promotes their activation, and leads to a blockade of tumor progression.
methodsBoth xenograft glioma and syngeneic glioma models were used to measure orthotopic tumor progression and overall survival. Flow cytometry and immunohistochemical analyses were performed to assess myeloid cell localization, recruitment, and activation.
resultsEcrg4 promotes monocyte recruitment and activation of microglia in a T-/B-cell-independent mechanism, which leads to a reduction in glioma tumor burden and increased survival. Mutational analysis reveals that the biological activity of Ecrg4 is dependent on a thrombin-processing site at the C-terminus, inducing monocyte invasion in vivo and in vitro. Furthermore, tumor-induced myeloid cell recruitment is impaired in Ecrg4 knockout mice, leading to increased tumor burden and decreased survival.
conclusionsTogether, these results identify Ecrg4 as a paracrine factor that activates microglia and is chemotactic for monocytes, with potential as an antitumor therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.